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Background: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer.
According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and
eribulin have been recognized as drugs with similar application for patients with advanced breast cancer. Although
there have been several case reports describing the efficacy of capecitabine against brain metastases, no report of
eribulin demonstrating efficacy for brain metastases exists today.
Case presentation: We describe a case of a 57-year-old Japanese woman who was diagnosed with breast cancer
stage IV metastasized to multiple organs including liver and lung. After she received 3 regimens, she showed
evidence of brain metastases, and whole brain radiation therapy was performed. Lapatinib and capecitabine was then
administered as fourth-line chemotherapy, but the patient was hospitalized due to the exacerbation of interstitial
pneumonitis and progression of brain and liver metastases. To control the systemic disease, eribulin was commenced
as fifth-line chemotherapy. One month later, a significant response of brain metastases had been achieved, and this
response has persisted for the last 4 months. We now describe a remarkable antitumor effect of eribulin against brain
metastases from breast cancer. This case is the first report which indicates potential treatment of brain metastases using
this medication.
Conclusion: This report suggests that eribulin treatment may be beneficial for breast cancer patients with brain
metastases progressing after whole brain radiation therapy. However, further clinical studies are warranted to
determine the clinical effect of eribulin in brain metastases.
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Eribulin is a recently approved new therapeutic option for
patients with metastatic breast cancer [1]. In a phase III
study, patients with brain metastases were excluded unless
these metastases had been previously treated and stabi-
lized [2]. Two phase II studies have excluded patients with
active symptomatic brain metastases or progression of
known brain metastases. However, the number of patients
with brain metastases in these trials was not reported
[3,4]. It is therefore important to evaluate the efficacy and
safety of eribulin in patients with brain metastases. In this
case, our patient experienced regression of brain metasta-
ses from breast cancer with eribulin.* Correspondence: matsuoka_h@med.kindai.ac.jp
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A 57-year-old Japanese female former smoker presented
at our hospital with a several months history of an occa-
sional bleeding from a lump on her left breast. She was
diagnosed with breast cancer with stage IV disease (cT4,
N3,M1) of invasive ductal carcinoma metastasized to
multiple organs including liver and lung. Pathological
evaluation revealed that the tumor was negative for hor-
mone receptor (HR) and positive for human epidermal
growth factor receptor 2 (HER2) defined by immunehis-
tochemistry and fluorescent in situ hybridization (FISH)
analyses, respectively (HR-/HER2+). She received 3 cycles
of first-line chemotherapy with paclitaxel (80 mg/m2,
weekly, intravenously, 3 weeks on/1 week off) and trastu-
zumab (4 mg/kg loading dose and 2 mg/kg, weekly ) from
October 2010 to January 2011, and the best response
was a partial response. After 3 months of first-lineral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 The effect of whole brain radiation therapy. After
whole brain radiation therapy, tumor regression was observed.
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tial pneumonitis, and the administration of paclitaxel was
discontinued. She was treated with oxygen and steroid-
pulse-therapy, and her symptoms gradually improved as
abnormal shadows on chest X-ray films were alleviated.
As a second-line treatment, doxorubicin (A) and cyclo-
phosphamide (C) (A: 40 mg/m2, C: 500 mg/m2, triweekly)
was commenced in February 2011. The best response was
a stable disease, and after 4 cycles of the second-line
chemotherapy, the disease eventually progressed. Trastu-
zumab (8 mg/kg loading dose and 6 mg/kg, triweekly) and
capecitabine (2,000 mg/m2, on days 1–14, q3w) was ad-
ministered in June 2011 as a third-line treatment. Al-
though the treatment achieved a partial response, grade 3
of hand foot syndrome (Common Terminology Criteria
for Adverse Events ver 4.0) emerged after 4 cycles of the
chemotherapy. We discontinued the treatment at once,
and observed an improvement of the hand foot syndrome.
After 6 cycles of the third-line chemotherapy, she showed
evidence of brain metastases (Figure 1), and whole brain
radiation therapy (WBRT) was performed in December
2011 (Figure 2). Lapatinib (1250 mg, orally, once daily)
and capecitabine (2,000 mg/m2, on days 1–14, triweekly)
was then administered as fourth-line chemotherapy in
January 2012, but the patient was hospitalized 3 months
later due to the exacerbation of interstitial pneumonitis
and progression of brain and liver metastases (Figure 3).Figure 1 The first evidence of brain metastases. After 6 cycles of
the 3rd-line chemotherapy, the first evidence of brain metastases
was shown. The arrow indicates appearance of the new
metastatic lesion.
Figure 3 Regrowth of the brain metastases. 4th-line chemotherapy
was administered, but patient was hospitalized again. Regrowth of
the brain metastases was detected. The arrow indicates the
recurrent tumor.
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pneumonia was improved again. To control the systemic
disease, eribulin (1.1 mg/m2, on days 1, 8, triweekly) was
commenced at the patient’s request in August 2012 as
fifth-line chemotherapy. One month later, a significant re-
sponse of brain metastases had been achieved (Figure 4),
and this response has persisted for the last 4 months.
According to preclinical study, eribulin has limited
ability to cross the blood brain barrier (BBB) [5-7]. Few
macromolecules are transferred into the brain because
vesicular transcytosis in the endothelial cells is con-
siderably limited and the tight junction is located be-
tween the endothelial cells. In addition, there are several
types of influx or efflux transporters at the BBB, such
as P-glycoprotein (P-gp), multidrug resistance-associated
protein, and breast cancer resistance protein [8,9]. Per-
meability in the BBB is increased by WBRT. One study
showed that radiation reduces P-gp expression in the
brain [10]. Therefore, it is likely that radiation allows eri-
bulin to enter into brain tissue and exert a significant
anti-tumor effect. However, the effect of a standard dose
WBRT persists only for 4 weeks after radiation therapy
(RT) [11], and attribution of the tumor regression to radio-
therapy in the present case could be very limited since
8 months have passed after radiotherapy. On the other
hand, brain metastases larger than 2 mm require angio-
genesis for growth and therefore newly formed capillaries
in brain metastases are fenestrated and they do not have a
normal functioning blood brain barrier. Eribulin is knownFigure 4 The effect of eribulin. After the administration of eribulin,
a significant response of brain metastases had been achieved. The
arrow indicates disappearance of the recurrent tumor.to be substrate for P-gp mediating drug efflux in BBB. But
there is a decreased expression of P-gp in the neovascula-
ture of brain metastases when compared to normal brain
tissue [12-14]. This might explain the positive effects of
eribulin on brain metastases.
There has been another reported case in which the treat-
ment of brain metastases from breast cancer with eribulin
in combination with WBRT was performed [15]. The pa-
tient continued chemotherapy and received concomitant
WBRT. After 3 cycles of eribulin mesylate, however, treat-
ment was discontinued because of newly diagnosed liver
metastases and progression in the lungs. Therefore, our
case is the first report which shows a favorable effect on
brain metastases. The treatment of eribulin was well toler-
ated without any high grade non-hematological toxicities,
and the hematological toxicity was also acceptable.
Capecitabine and eribulin have been recognized as
drugs with similar application for the patients with ad-
vanced breast cancer. Although there have been several
case reports describing the efficacy of capecitabine
against brain metastases from breast cancer, no report of
eribulin demonstrating efficacy for brain metastases ex-
ists to date. Thus, the current case report is of value,
and may help physicians determine which option to
choose in treating patients with brain metastases.Conclusion
This report suggests that eribulin treatment may be bene-
ficial for breast cancer patients with brain metastases pro-
gressing after WBRT. However, further clinical studies are
warranted to determine the clinical effect of eribulin in
brain metastases.Consent
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